IL44011A - Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them - Google Patents

Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them

Info

Publication number: IL44011A
Authority: IL; Israel
Prior art keywords: cell; virus; process according; suspension; polyvinylpyrrolidone
Prior art date: 1973-02-09

Application number

IL44011A

Other languages

English (en)

Other versions

IL44011A0 (en

Inventor

N Zygraich

J Peetermans

Original Assignee

Rit Rech Ind Therapeut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-02-09

Filing date

1974-01-16

Publication date

1977-04-29

1974-01-16 Application filed by Rit Rech Ind Therapeut filed Critical Rit Rech Ind Therapeut

1974-05-16 Publication of IL44011A0 publication Critical patent/IL44011A0/xx

1977-04-29 Publication of IL44011A publication Critical patent/IL44011A/en

Links

241000700605 Viruses Species 0.000 title claims abstract description 54
230000000087 stabilizing effect Effects 0.000 title claims abstract description 27
239000000203 mixture Substances 0.000 title claims abstract description 26
238000002360 preparation method Methods 0.000 title claims abstract description 14
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 16
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 16
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 16
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
229930006000 Sucrose Natural products 0.000 claims abstract description 8
239000005720 sucrose Substances 0.000 claims abstract description 8
239000002738 chelating agent Substances 0.000 claims abstract description 7
239000008366 buffered solution Substances 0.000 claims abstract description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 5
229930195712 glutamate Natural products 0.000 claims abstract description 3
239000000725 suspension Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 12
229910052751 metal Inorganic materials 0.000 claims description 6
239000002184 metal Substances 0.000 claims description 6
241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims description 5
150000001768 cations Chemical class 0.000 claims description 5
-1 edetate alkali metal salt Chemical class 0.000 claims description 5
239000000243 solution Substances 0.000 claims description 5
241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 4
229940009662 edetate Drugs 0.000 claims 1
239000008363 phosphate buffer Substances 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 claims 1
238000004108 freeze drying Methods 0.000 abstract description 11
238000003860 storage Methods 0.000 abstract description 11
238000000605 extraction Methods 0.000 abstract description 7
229960005486 vaccine Drugs 0.000 abstract description 7
210000004027 cell Anatomy 0.000 description 28
239000000463 material Substances 0.000 description 12
239000000126 substance Substances 0.000 description 7
210000002950 fibroblast Anatomy 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
239000002054 inoculum Substances 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical group FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
229940037001 sodium edetate Drugs 0.000 description 4
238000000527 sonication Methods 0.000 description 4
208000006758 Marek Disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
235000021120 animal protein Nutrition 0.000 description 3
239000007640 basal medium Substances 0.000 description 3
244000309466 calf Species 0.000 description 3
210000003837 chick embryo Anatomy 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000004448 titration Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
102000004407 Lactalbumin Human genes 0.000 description 2
108090000942 Lactalbumin Proteins 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229940061607 dibasic sodium phosphate Drugs 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
239000000413 hydrolysate Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
235000013919 monopotassium glutamate Nutrition 0.000 description 2
239000004239 monopotassium glutamate Substances 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
HQEROMHPIOLGCB-DFWYDOINSA-M potassium;(2s)-2-aminopentanedioate;hydron Chemical compound [K+].[O-]C(=O)[C@@H](N)CCC(O)=O HQEROMHPIOLGCB-DFWYDOINSA-M 0.000 description 2
239000000047 product Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
229940124863 Varicella-zoster virus vaccine Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
244000144992 flock Species 0.000 description 1
239000012530 fluid Substances 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000000601 reactogenic effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16351—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IL44011A 1973-02-09 1974-01-16 Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them IL44011A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US330912A US3915794A (en)	1973-02-09	1973-02-09	Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them

Publications (2)

Publication Number	Publication Date
IL44011A0 IL44011A0 (en)	1974-05-16
IL44011A true IL44011A (en)	1977-04-29

Family

ID=23291840

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL44011A IL44011A (en)	1973-02-09	1974-01-16	Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them

Country Status (18)

Country	Link
US (1)	US3915794A (nl)
JP (1)	JPS5732043B2 (nl)
AT (1)	AT331398B (nl)
BE (1)	BE810555A (nl)
CA (1)	CA1035700A (nl)
CH (1)	CH592143A5 (nl)
DD (1)	DD110306A5 (nl)
DE (1)	DE2406167C2 (nl)
DK (1)	DK134032B (nl)
ES (1)	ES422961A1 (nl)
FR (1)	FR2216997B1 (nl)
GB (1)	GB1452344A (nl)
HU (1)	HU169120B (nl)
IE (1)	IE38825B1 (nl)
IL (1)	IL44011A (nl)
NL (1)	NL178013C (nl)
SE (1)	SE427799B (nl)
ZA (1)	ZA74163B (nl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57114527A (en) *	1979-10-29	1982-07-16	Merck & Co Inc	Vaccine stabilizer
PT71926B (en) *	1979-10-29	1982-03-31	Merck & Co Inc	Process for preparing a liquid vaccine comprising a stabilizer
US4273762A (en) *	1979-12-03	1981-06-16	Merck & Co., Inc.	Lyophilization process for live viral compositions
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
ZA874625B (en) *	1986-06-30	1988-10-26	Smith Kline Rit	Stabilizers for live vaccines,process for their preparation and vaccines containing them
US4847078A (en) *	1987-01-14	1989-07-11	Arseco, Inc.	Storage stable topical composition having moisture control agent
JPH01112853U (nl) *	1988-01-27	1989-07-28
IL90188A0 (en) *	1988-05-18	1989-12-15	Cryopharm Corp	Process and medium for the lyophilization of erythrocytes
US5045446A (en) *	1988-08-26	1991-09-03	Cryopharm Corporation	Lyophilization of cells
JPH05501419A (ja) *	1990-05-25	1993-03-18	コーブ　ラボラトリーズ　インコーポレイテッド	生体適合性、両親媒性ポリマー混合物中の細胞、細胞―様物質および小板の凍結乾燥法
AU2088992A (en) *	1992-05-05	1993-11-11	Research Foundation For Microbial Diseases Of Osaka University, The	Stabilized live vaccine
US5360736A (en) *	1992-06-04	1994-11-01	Merck & Co., Inc.	Process for attenuated varicella zoster virus vaccine production
RU2126269C1 (ru) *	1992-06-04	1999-02-20	Мерк Энд Ко., Инк.	Способ получения вакцины, способ получения свободной от клеток вакцины, способ культивирования клеток, питательная среда
CA2158935A1 (en) *	1993-10-12	1995-04-20	Chiron Viagene, Inc.	Methods for preserving recombinant viruses
ES2234018T3 (es) *	1996-04-26	2005-06-16	MERCK & CO., INC.	Formulaciones de vacunas de adn.
ZA973642B (en) *	1996-04-26	1997-11-25	Merck & Co Inc	DNA vaccine formulations.
US6051238A (en) *	1996-12-20	2000-04-18	Merck & Co., Inc.	Stabilizers for lyophilized mumps vaccines
US6210683B1 (en)	1997-09-05	2001-04-03	Merck & Co., Inc.	Stabilizers containing recombinant human serum albumin for live virus vaccines
US6926897B1 (en) *	1998-03-24	2005-08-09	Medigene Aktiengesellschaft	Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19812940A1 (de) *	1998-03-24	1999-10-07	Medigene Ag	Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
GB9808922D0 (en) *	1998-04-24	1998-06-24	Cantab Pharmaceuticals Res Ltd	Virus preparations
US6225289B1 (en)	1998-12-10	2001-05-01	Genvec, Inc.	Methods and compositions for preserving adenoviral vectors
RU2144376C1 (ru) *	1999-06-28	2000-01-20	Всероссийский научно-исследовательский институт защиты животных	Сухая вирусвакцина против болезни марека и способ ее изготовления
RU2144378C1 (ru) *	1999-06-28	2000-01-20	Всероссийский научно-исследовательский институт защиты животных	Вирусвакцина против болезни марека и способ ее изготовления
FR2814957B1 (fr) *	2000-10-06	2002-12-20	Aventis Pasteur	Composition vaccinale et procede de stabilisation
US7013940B2 (en) *	2001-04-19	2006-03-21	Michelin Recherche Et Technique S.A.	Device for attenuating cavity noise in a tire and wheel
ATE300954T1 (de) *	2001-12-10	2005-08-15	Bavarian Nordic As	Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
TWI398272B (zh) *	2005-03-08	2013-06-11	Intervet Int Bv	化學定義的安定劑
EP1870649A1 (en)	2006-06-20	2007-12-26	Octapharma AG	Lyophilisation targetting defined residual moisture by limited desorption energy levels
LT2741740T (lt)	2011-08-12	2017-08-10	Merial, Inc.	Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
TWI690322B (zh)	2012-10-02	2020-04-11	法商傳斯堅公司	含病毒的調配物及其使用
EP3142486B1 (en)	2014-05-14	2026-03-11	Boehringer Ingelheim Vetmedica GmbH	Methods for freeze-drying and rehydrating biologics
AU2015357225B2 (en) *	2014-12-01	2020-04-09	Transgene Sa	Stable liquid vaccinia virus formulations
CN105999287A (zh) *	2016-07-01	2016-10-12	广东圣戈生物科技有限公司	一种疫苗稀释液及其制备方法
CA3037544C (en)	2016-10-05	2021-10-12	Zoetis Services Llc	Lyophilization methods that provide stably dehydrated protozoans for use as potent live vaccines
CN111065732A (zh)	2017-09-11	2020-04-24	Imba-莫利库尔生物技术研究所	肿瘤类器官模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1292803A (en) *	1968-11-18	1972-10-11	Nat Res Dev	Improvements relating to the production of antigens
US3642574A (en) *	1970-04-29	1972-02-15	Us Agriculture	Method for producing vaccine for immunization of poultry against marek{3 s disease
US3783098A (en) *	1971-08-10	1974-01-01	Cornell Res Foundation Inc	Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same

1973
- 1973-02-09 US US330912A patent/US3915794A/en not_active Expired - Lifetime
1974
- 1974-01-09 ZA ZA740163A patent/ZA74163B/xx unknown
- 1974-01-16 IL IL44011A patent/IL44011A/en unknown
- 1974-01-17 FR FR7401572A patent/FR2216997B1/fr not_active Expired
- 1974-02-04 IE IE203/74A patent/IE38825B1/xx unknown
- 1974-02-04 CH CH151774A patent/CH592143A5/xx not_active IP Right Cessation
- 1974-02-04 CA CA191,632A patent/CA1035700A/en not_active Expired
- 1974-02-04 BE BE140507A patent/BE810555A/xx unknown
- 1974-02-06 SE SE7401554A patent/SE427799B/xx not_active IP Right Cessation
- 1974-02-06 DK DK64774A patent/DK134032B/da not_active IP Right Cessation
- 1974-02-06 ES ES422961A patent/ES422961A1/es not_active Expired
- 1974-02-07 JP JP1581474A patent/JPS5732043B2/ja not_active Expired
- 1974-02-07 AT AT98274A patent/AT331398B/de not_active IP Right Cessation
- 1974-02-07 GB GB559574A patent/GB1452344A/en not_active Expired
- 1974-02-08 DE DE2406167A patent/DE2406167C2/de not_active Expired
- 1974-02-08 DD DD17647674A patent/DD110306A5/xx unknown
- 1974-02-08 HU HURE000547 patent/HU169120B/hu not_active IP Right Cessation
- 1974-02-08 NL NLAANVRAGE7401786,A patent/NL178013C/nl not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK134032B (da)	1976-08-30
HU169120B (nl)	1976-09-28
DD110306A5 (nl)	1974-12-12
IL44011A0 (en)	1974-05-16
GB1452344A (en)	1976-10-13
DE2406167A1 (de)	1974-08-15
BE810555A (fr)	1974-08-05
CA1035700A (en)	1978-08-01
IE38825B1 (en)	1978-06-07
US3915794A (en)	1975-10-28
IE38825L (en)	1974-08-09
AU6486574A (en)	1975-07-24
AT331398B (de)	1976-08-25
JPS49109518A (nl)	1974-10-18
ZA74163B (en)	1974-11-27
DK134032C (nl)	1977-02-07
FR2216997A1 (nl)	1974-09-06
FR2216997B1 (nl)	1978-01-06
SE427799B (sv)	1983-05-09
ES422961A1 (es)	1976-06-01
JPS5732043B2 (nl)	1982-07-08
NL7401786A (nl)	1974-08-13
ATA98274A (de)	1975-11-15
CH592143A5 (nl)	1977-10-14
NL178013C (nl)	1986-01-02
NL178013B (nl)	1985-08-01
DE2406167C2 (de)	1984-12-20

Publication	Publication Date	Title
US3915794A (en)	1975-10-28	Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
Kawai et al.	1973	Isolation of defective mutant of avian sarcoma virus
US3783098A (en)	1974-01-01	Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US6210683B1 (en)	2001-04-03	Stabilizers containing recombinant human serum albumin for live virus vaccines
Finberg et al.	1979	Generation of cytolytic T lymphocytes after reovirus infection: role of S1 gene.
RU2126269C1 (ru)	1999-02-20	Способ получения вакцины, способ получения свободной от клеток вакцины, способ культивирования клеток, питательная среда
EP0048201B1 (en)	1985-04-10	Herpes simplex type i fraction vaccine and process for its preparation
CA2873775C (en)	2021-04-20	Herpesvirus compositions and related methods
Stohrer et al.	1979	Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product
CA1095407A (en)	1981-02-10	Preparation for the treatment of herpes zoster and other herpes infections, as well as method for manufacture thereof
CA1109393A (en)	1981-09-22	Vaccine and its preparation
Patrascu et al.	1972	Vaccination with lyophilized turkey herpesvirus (HVT): minimum infective and protective doses
JPS6314729A (ja)	1988-01-21	生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン
NZ195836A (en)	1984-02-03	Method of recovering neoantigens from virus-infected cells;feline leukemia vaccine
US4351827A (en)	1982-09-28	Novel polyvalent virus vaccine
US20050084503A1 (en)	2005-04-21	Continuous cell line for the production of vaccines
US5378467A (en)	1995-01-03	Cell-free Marek's disease virus vaccine
AU622110B2 (en)	1992-04-02	A stable lyophilized live herpes virus vaccine
EP0760394A1 (en)	1997-03-05	Mild Newcastle disease virus vaccine
EP0008255B1 (en)	1983-04-13	Herpes virus vaccine and its preparation
Schat et al.	1978	In vitro inactivation of cell-free Marek's disease herpesvirus by immune peripheral blood lymphocytes
US3733401A (en)	1973-05-15	Highly attenuated newcastle disease virus vaccine and production thereof
RU2637093C1 (ru)	2017-11-29	Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
US4358438A (en)	1982-11-09	Novel polyvalent virus vaccine against rabies and canine distemper
Tzipori	1975	The isolation of bovine ephemeral fever virus in cell cultures and evidence for autointerference